Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Lispro Mid Mixture vs Glargine + Lispro in T2D
NCT00377858Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2006
- Primary completion
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of insulin lispro + insulin lispro protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 36 weeks. Started Aug 2006; status: completed.
02
Drugs
insulin lispro + insulin lispro protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00377858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377858.